Objective—To evaluate changes in characteristics of feline injection-site sarcomas (ISSs) from 1990 through 2006.
Design—Retrospective case series.
Animals—392 cats with a histologic diagnosis of soft tissue sarcoma, osteosarcoma, or chondrosarcoma at potential injection sites.
Procedures—Classification and anatomic location of tumors and signalment of affected cats were compared between ISSs diagnosed before and after publication of the Vaccine Associated Feline Sarcoma Task Force vaccination recommendations in 1996.
Results—From before to after publication of the vaccination recommendations, proportions of ISSs significantly decreased in the interscapular (53.4% to 39.5%) and right and left thoracic (10.2% to 3.6% and 9.1% to 1.3%, respectively) regions. On the other hand, proportions of ISSs significantly increased in the right thoracic limb (1.1% to 9.5%) and the combined regions of the right pelvic limb with right lateral aspect of the abdomen (12.5% to 25.0%) and the left pelvic limb with left lateral aspect of the abdomen (11.4% to 13.8%). Patterns of tumor classification and signalment did not change.
Conclusions and Clinical Relevance—Despite publication of the vaccination recommendations, a high proportion of tumors still developed in the interscapular region. There was also an increase in lateral abdominal ISSs, which are more difficult to treat and are likely attributable to aberrant placement of injections intended for the pelvic limbs. Veterinarians are complying with vaccination recommendations to some extent, but they need to focus on administering vaccines as distally as possible on a limb to allow for complete surgical margins if amputation of a limb is required.
Objective—To determine the seroprevalence of antibodies
against Bartonella spp in a population of sick
dogs from northern California and identify potential
risk factors and clinical signs associated with seropositivity.
Sample Population—Sera from 3,417 dogs.
Procedure—Via an ELISA, sera were analyzed for
antibodies against Bartonella vinsonii subsp berkhoffii,
Bartonella clarridgeiae, and Bartonella henselae;
test results were used to classify dogs as seropositive
(mean optical density value ≥ 0.350 for B henselae
or ≥ 0.300 for B clarridgeiae or B vinsonii subsp
berkhoffii) or seronegative. Overall, 305 dogs (102
seropositive and 203 seronegative dogs) were included
in a matched case-control study.
Results—102 of 3,417 (2.99%) dogs were seropositive
for ≥ 1 species of Bartonella. Of these, 36 (35.3%)
had antibodies against B henselae only, 34 (33.3%)
had antibodies against B clarridgeiae only, 2 (2.0%)
had antibodies against B vinsonii subsp berkhoffiionly ,
and 30 (29.4%) had antibodies against a combination
of those antigens. Compared with seronegative dogs,
seropositive dogs were more likely to be herding dogs
and to be female, whereas toy dogs were less likely to
be seropositive. Seropositive dogs were also more
likely to be lame or have arthritis-related lameness,
nasal discharge or epistaxis, or splenomegaly.
Conclusions and Clinical Relevance—Only a small
percentage of dogs from which serum samples were
obtained had antibodies against Bartonella spp. Breed
appeared to be an important risk factor for seropositivity.
Bartonella infection should be considered in
dogs with clinical signs of lameness, arthritis-related
lameness, nasal discharge or epistaxis, or
splenomegaly. (Am J Vet Res 2005;66:688–694)